2015, Number 2
<< Back Next >>
Med Int Mex 2015; 31 (2)
Tenofovir and its relation to osteoporosis in HIV-patients
Cruz-Rodríguez A, Castro-D’Franchis LJ, Reyes-Jiménez AE
Language: Spanish
References: 18
Page: 150-154
PDF size: 378.91 Kb.
ABSTRACT
Background: Osteoporosis, a disease with high prevalence, is characterized
by decreased bone mass, deterioration of bone tissue, disruption
of bone architecture and commitment in bone strength, increasing the
risk of fracture. Osteoporosis is common in patients with HIV and is
a major cause of morbidity and mortality. HAART has dramatically changed the course of HIV infection transforming a fatal infection to
a chronic disease and relatively manageable, improving both survival
and quality of life. In particular, bone alterations have been observed in
the course of HIV infection, becoming a key point for the management
of patients with HIV, especially for possible development of fractures,
determining major comorbidities.
Objective: To determine if tenofovir causes osteopenia in HIV-patients.
Material and method: An ambispective, cross-sectional, analytical,
observational study was done with patients with HIV diagnosis receiving
treatment with tenofovir, attended at HIV Clinic of North Central Hospital,
Pemex, Mexico City; patients were submitted to bone densitometry
and viral load determination.
Results: 85.8% of patients with undetectable viral load had osteopenia;
also, the variable treatment was the only responding quantitatively to
the verification of the hypothesis that treatment with tenofovir worsens
osteoporosis-osteopenia.
Conclusions: There are more cases of reduced bone mineral density
related to administration of tenofovir. This drug causes osteopenia in patients,
depending on the time of administration and related comorbidities.
REFERENCES
Carrero A, Ryan P. Tenofovir y enfermedad ósea en pacientes infectados por el VIH. Servicio de Medicina Interna, Hospital España, 2009.
Cosman F, Lindsay R. Clinicians guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, 2014 Issue, Version 1.
Martínez E, Jódar Gimeno E y col. Documento de consenso: Recomendaciones para el manejo de la enfermedad ósea metabólica en pacientes con VIH. Enfermedades Infecciosas y Microbiología Clínica 2014;32.
McComsey G, Tebas P, Shane E, etal. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis 2010;51:937-946.
Challenges in the management of osteoporosis and vitamin D deficiency in HIV infection. Osteoporosis and Vitamin D Deficiency in HIV Infection. 2013;21:115-118.
Sharp M. HIV and bone health. BETA 2011;23:28-37.
Harrison. Principios de Medicina Interna. 18a ed. McGraw-Hill.
Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS 2009;23:1297-1310.
Farreras. Medicina Interna 17a ed. México: Elsevier, 2012;1024-1029.
Bedimo R, Maalouf N, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012;26:825-831.
Hofbauer L, Hamann C, Ebeling P. Approach to the patient with secondary osteoporosis. Eur J Endocrinol 2010;162:1009-1020.
Haskelber H, Carr A, Emery S. Bone turnover markers in HIV disease. AIDS review 2011;13:240-250.
Saccomanno M, Ammassari A. Bone disease in HIV infection. Clin Cases Mineral Bone Metab 2011;8:33-36.
Mateo L, Holgado S, Mariñoso ML. Hypophosphatemic osteomalacia induced by tenofovir en HIV-infected patients. Clin Rheumatol 2014.
Walker HV, Brown TT. Bone loss in the HIV- infected patient: Evidence, clinical implications, and treatment strategies. J Infect Disease 2012;205:391-398.
EACS. European AIDS Clinical Society. European AIDS Clinical Society guidelines: Prevention and management of non-infectious co-morbidities in HIV. October 2013.
Marshall D, Johnell O, Wedel H. Meta analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 2000;312:1254-1259.
Hans DB, Shepherd JA, Schwartz EN, et al. Peripheral dual energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official positions. J Clin Densitom 2008;11:188-206.
Full text